On November 19, 2018, the fourth National Prize for Import Substitution Award Ceremony PRIORITY-2018 was held in the Big Hall of the Public Chamber of the Russian Federation.
The authoritative award has traditionally awarded to the best enterprises that have achieved the greatest success in import substitution. The ceremony was attended by the representatives of the Ministry of Industry and Trade of Russia, committees of the State Duma, the Chamber of Commerce and Industry and the Industrial Development Fund.
282 products, presented by 160 companies from 51 regions of the Russian Federation and 20 sectors of the economy competed for the award in 30 categories.
The FSUE Moscow Endocrine Plant won the Priority Innovation nomination having presented the new drug Morphine hydrochloride, 5 and 10 mg coated tablets.
The drug was developed by the FSUE Moscow Endocrine Plant pursuant to the Action Plan "Improvement of the Availability of Narcotic Drugs and Psychotropic Substances for Medical Use (Roadmap)", approved by the Order of the Government of the Russian Federation from July 1, 2016 No. 1403-r. The drug is the gold standard for pain control and is recommended by the World Health Organization. The introduction of the drug Morphine, 5 mg and 10 mg film-coated tablets for non-invasive treatment of pain syndrome allows to expand the possibilities of provision of palliative care on an outpatient basis and will improve significantly the quality of life of patients. Until recently this drug was not registered in Russia and patients were not able to use it. Now the drug is supplied to all constituent entities of the Russian Federation.
The employees of the Enterprise - Irina Dorofeeva, the head of the department for external communications and organization of personnel training and Oksana Grigoryeva, the head of the drug implementation department - took part in the award ceremony.
Comment type is not specified in the component properties.